AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02280473
Drug: REFRESH LIQUIGEL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Trial: NCT03647852
Drug: other basic supportive treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d
Trial: NCT01231230
Drug: placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhalation once
Trial: NCT00686803
Drug: PL3994
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug
Trial: NCT00686803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00664014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
Trial: NCT02411448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT02861300
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Trial: NCT02861300
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Trial: NCT04458272
Drug: DS-1001b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg, twice daily, continuous oral administration
Trial: NCT01388920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01775462
Drug: EDI200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 or 10 mg/kg of EDI200
Trial: NCT00972855
Drug: Casodex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Tablet
Trial: NCT01193517
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
Trial: NCT00775385
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
Trial: NCT00775385
Drug: Customized Treatment
RxNorm normalized name: SULFUR 3 mg in 100 mL TOPICAL CREAM [MDacne Customized Cream (Sulfur)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)
Trial: NCT00209209
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT00209209
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT03221946
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet of 50mg,
Trial: NCT03221946
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal patch 100 mg
Trial: NCT03221946
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intra muscular injection 100mg
Trial: NCT04324164
Drug: Third-generation EGFR-TKI
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
Trial: NCT01491490
Drug: GWP42003 : GWP42004 (40:1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken once a day for 6 weeks
Trial: NCT01491490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken once a day for 6 weeks
Trial: NCT00042367
Drug: Induction therapy (Regimen 1, Course 1, Cycle A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)
Trial: NCT00042367
Drug: Regimen 1, Course 1, Cycle A2 (Days 22 - 42)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
Trial: NCT03956446
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
Trial: NCT03956446
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Trial: NCT04181762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00002970
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00042367
Drug: Cycle B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1.
Trial: NCT00042367
Drug: Regimen 1, Course 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
Trial: NCT00042367
Drug: Regimen 2, Course 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir.
Trial: NCT00042367
Drug: Regimen 2, Course, 1, Cycle C1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2.
Trial: NCT00042367
Drug: Regimen 2, Course 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
Trial: NCT06385977
Drug: medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of medication
Trial: NCT02776371
Drug: Modified non-clarithromycin triple therapy
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
Trial: NCT02776371
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
Trial: NCT02061800
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
Trial: NCT02320318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
Trial: NCT00560183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT02378350
Drug: Peritoneal Dialysis treatment (no specific drug is defined)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02935101
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: formulated for oral administration. encapsulated.
Trial: NCT02935101
Drug: Placebo (for Prednisolone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Prednisolon 10mg capsules
Trial: NCT01213550
Drug: Placebo mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00417573
Drug: IV Gamunex 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04471597
Drug: normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
Trial: NCT01880099
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo compared to 8mg of Galantamine
Trial: NCT03083132
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule oral daily
Trial: NCT01473056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, twice a day or three times a day for 3 days
Trial: NCT01936077
Drug: Recombinant LH (Luveris)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU recombinant LH daily.
Trial: NCT00563303
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
Trial: NCT01721070
Drug: Sufentanil NanoTab (SUF NT) 15 mcg
RxNorm normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1: One dose of SUF NT 15 mcg administered sublingually
Trial: NCT01721070
Drug: Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
Trial: NCT06478355
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
Trial: NCT00687232
Drug: AZD4818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
Trial: NCT00687232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03163784
Drug: Antibiotic Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets manufactured to mimic antibiotics
Trial: NCT00092690
Drug: MK0653A, ezetimibe (+) simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01520454
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
Trial: NCT01805271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (5 or 10 mg/day, i.e. 1 or 2 tablets/day)
Trial: NCT01122472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 3 weeks every 4 weeks for 24 months
Trial: NCT00543738
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01522729
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
Trial: NCT01522729
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo \[NaCl\]
Trial: NCT00218127
Drug: Levoacetyl Methadol
RxNorm normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
Trial: NCT00218127
Drug: Levoacetyl Methadol
RxNorm normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
Trial: NCT00218127
Drug: Levoacetyl Methadol
RxNorm normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM Fixed Dose evaluation up to 48 mg 48 mg
Trial: NCT03813771
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
Trial: NCT06202456
Drug: Huazhi Rougan granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huazhi Rougan granule
Trial: NCT01464944
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
Trial: NCT01464944
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
Trial: NCT01464944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
Trial: NCT00650234
Drug: Glucophage® XR Tablets 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, single dose fasting
Trial: NCT03011333
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
Trial: NCT03011333
Drug: Bupivacaine HCl without epinephrine
RxNorm normalized name: bupivacaine hydrochloride / epinephrine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl without epinephrine, 50 mg via nerve block.
Trial: NCT03011333
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo via nerve block.
Trial: NCT02309918
Drug: LDV/SOF FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
Trial: NCT06135675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration orally.
Trial: NCT03131453
Drug: CNP520 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule
Trial: NCT03131453
Drug: CNP520 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg capsule
Trial: NCT04096170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
Trial: NCT02378623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
Trial: NCT02497300
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02497300
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01213355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, single dose, oral, 1 day
Trial: NCT01321112
Drug: conversion from CNI to MMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
Trial: NCT04245371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Patch
Trial: NCT03673384
Drug: Xyzal Oral Product
RxNorm normalized name: Xyzal Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
Trial: NCT01049399
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: powder for oral suspension administered once daily in fasting conditions for 52 weeks
Trial: NCT02298504
Drug: Biodentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital pulp therapy
Trial: NCT02614703
Drug: Chromoendoscopy using Acetic Acid 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spraying esophageal mucosa during random biopsies for Barrett's esophagus
Trial: NCT01265888
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM